Aricept (donepezil hydrochloride) + Aricept (donepezil hydrochloride) + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Down Syndrome
Conditions
Down Syndrome, Cognitive Dysfunction
Trial Timeline
Sep 1, 2008 → Dec 1, 2008
NCT ID
NCT00754052About Aricept (donepezil hydrochloride) + Aricept (donepezil hydrochloride) + Placebo
Aricept (donepezil hydrochloride) + Aricept (donepezil hydrochloride) + Placebo is a phase 3 stage product being developed by Eisai for Down Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00754052. Target conditions include Down Syndrome, Cognitive Dysfunction.
What happened to similar drugs?
1 of 2 similar drugs in Down Syndrome were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00754052 | Phase 3 | Terminated |
Competing Products
13 competing products in Down Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg) | Yuhan | Phase 1 | 29 |
| Aricept (Donepezil hydrochloride) + Placebo | Eisai | Phase 3 | 32 |
| Donepezil hydrochloride (Aricept) | Eisai | Phase 2 | 27 |
| E2020-Donepezil hydrochloride + E2020-Donepezil hydrochloride + Placebo | Eisai | Phase 2 | 35 |
| Donepezil HCl + Placebo | Eisai | Phase 2 | 35 |
| Donanemab + Placebo | Eli Lilly | Approved | 50 |
| Placebo + RG1662 | Roche | Phase 1 | 29 |
| Placebo + RG1662 + RG1662 | Roche | Phase 2 | 35 |
| Placebo + RO5186582 | Roche | Phase 2 | 27 |
| RG1662 + placebo | Roche | Phase 1 | 29 |
| ELND005 + Placebo | Elanco | Phase 2 | 32 |
| ACI-24 low dose + ACI-24 high dose + Placebo | AC Immune | Phase 1 | 19 |
| ACI-24 + Placebo | AC Immune | Phase 2 | 17 |